FDA (Image: AP)

FDA ex­perts vote to yank the agen­cy's 2011 OK of con­tro­ver­sial preterm birth drug af­ter a tri­al fail­ure

Should AM­AG con­tin­ue to be al­lowed to sell their ther­a­py for pre­vent­ing preterm births even though their long-run­ning con­fir­ma­to­ry study flopped — bad­ly?

That was …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.